文献速递泌尿生殖介入MRPETCT

1.5T MRI-Linac引导PSMA-PET/CT靶向SBRT治疗寡转移性去势敏感前列腺癌的可行性与急性患者报告结局初步数据

Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
PubMed 文献 · Radiol Med · 2021-04-09

中位PSA由治疗前1.16 ng/mL降至首次随访0.44 ng/mL,16例可检测PSA者中6例部分缓解、10例完全缓解,无急性≥2级毒性,耐受性良好。

要点

  • PSMA-PET/CT引导下1.5T MRI-Linac行SBRT对寡复发前列腺癌可行且耐受良好。
  • 治疗后中位PSA由1.16 ng/mL降至0.44 ng/mL,未见急性≥2级毒性。
  • 最常见治疗部位为淋巴结(16个)和骨盆骨(9个)。

核心结论

  • PSMA-PET/CT引导下1.5T MRI-Linac行SBRT治疗去势敏感寡复发前列腺癌是可行且耐受良好的,初步疗效令人鼓舞。

研究设计与样本

  • 前瞻性观察研究,2019年10月至2020年4月连续纳入20例去势敏感寡复发前列腺癌患者,经伦理委员会批准(方案号XXXX)。
  • 采用1.5T MRI-Linac(Unity,Elekta AB,斯德哥尔摩,瑞典)在PSMA-PET/CT引导下行SBRT,平均剂量35 Gy分5次。
  • 毒性按CTCAE v5.0前瞻性收集,生活质量采用EORTC-QLQ C30问卷在基线、治疗结束和首次随访时评估。

诊断标准与关键数值

  • SBRT前中位PSA为1.16 ng/mL(范围0.27-8.9),首次随访中位PSA为0.44 ng/mL(范围0.06-8.15)。
  • 首次随访时16例PSA可检测者行PSMA-PET/CT,6例部分缓解、10例完全缓解;其余病例PSA不可检测。
  • 未记录到急性≥2级毒性。

临床应用与阅片要点

  • 对于去势敏感寡复发前列腺癌,可考虑PSMA-PET/CT引导下1.5T MRI-Linac行SBRT作为治疗选择。
  • 治疗后应监测PSA并用PSMA-PET/CT评估代谢反应,本研究中部分缓解与完全缓解均可出现。

局限性

  • 随访时间短,仅报告急性毒性和首次随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To report preliminary data on feasibility and patient-reported outcomes following PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac.

METHODS AND MATERIALS: Between October 2019 and April 2020, twenty consecutive castration sensitive oligorecurrent prostate cancer patients were enrolled in an ethical committee approved prospective observational study (Protocol n. XXXX) and treated with PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac (Unity, Elekta AB, Stockholm, Sweden). The mean delivered dose was 35 Gy in 5 fractions. Clinicians reported toxicity was prospectively collected according to Common Terminology Criteria for Adverse Events v5.0. Quality of life (QoL) assessment was performed using EORTC-QLQ C30 questionnaires administered at baseline, end of treatment and at first follow-up.

RESULTS: Twenty-five lesions in 20 castration sensitive oligorecurrent patients were treated: the most commonly treated anatomic sites were nodal (n = 16) and pelvic bone (n = 9). Median PSA-value preMRI guided SBRT was 1.16 ng/mL (range, 0.27-8.9), whereas median PSA value at first follow-up after SBRT was 0.44 ng/mL (range, 0.06-8.15). At first follow-up, for 16 patients showing detectable PSA, PSMA-PET/CT was performed detecting, respectively, in 6 cases partial response and in 10 cases complete response. In the remaining cases, PSA-value was undetectable after SBRT. Radiotherapy treatment was safe and well tolerated according to the PROMs. No acute G2 or higher toxicities were recorded.

CONCLUSIONS: The current series represent the largest one exploring the feasibility and patient-reported outcomes following PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac. The preliminary findings here reported are encouraging in terms of effectiveness and tolerability.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Mazzola R, Cuccia F, Figlia V, et al. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. Radiol Med. 2021. PMID: 33835309. doi:10.1007/s11547-021-01352-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。